Inhalation characteristics and their effects on in vitro drug delivery front dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers

International Journal of Pharmaceutics

Volumn 138, Issue 1, 1996, Pages 45-56

  De Boer, A H ^a   Gjaltema, D ^a   Hagedoorn, P ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Asthma; Cascade impactor; COPD; Dry powder inhalers; In vitro deposition; Inspiration time; Peak flow rate (PIFR); Work of inspiration

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CROMOGLYCATE DISODIUM;

AEROSOL; ARTICLE; ASTHMA; BREATHING; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG RELEASE; INHALATION; INSPIRATORY CAPACITY; PARTICLE SIZE; PEAK EXPIRATORY FLOW; POWDER; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

EID: 0030581128     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)04526-7     Document Type: Article

References (12)

1. Bell, J.H., Hartley, P.S. and Cox, J.S.G., Dry powder aerosols I: a new powder inhalation device. J. Pharm. Sci., 60 (1971) 1559-1564.
2. De Boer, A.H., Lerk, C.F. and Winter, H.M.I., Effect of inhalation mode on in-vitro drug deposition from three different types of commercial dry powder inhalers. Int. J. Pharm., 130 (1996) 231-244.
3. Holmann, J.Ch., Schibler, A. and Kraemer, R., Charakteristika der inspiratorischen Fluss-Volumen-Kurven bei Kindern mit Asthma bronchiale und Patienten mit zystischer Fibrose. Schweiz. med. Wschr., 119 (1989) 1713-1718.
4. Matthys, H., 1994 Können Pulverinhalatoren Treibgasdosieraerosole ersetzen? Atemw.-Lungenkrkh., 20 (1994) 277-283.
5. Newman, S.P. and Pavia, D., Aerosol deposition in man. In Morén, F., Newhouse, M.T. and Dolovich, M.B. (Eds), Aerosols in Medicine, Elsevier, Amsterdam, 1985, pp. 193 217.
6. Olsson, B., In vitro studies of budesonide and terbutaline Turbuhaler. In Proceedings of the 8th Congress of the International Society for Aerosols in Medicine, Davos, Switzerland, 1991.
7. Sumby, B.S., Churcher, K.M., Smith, I.J., Grant, A.C., Truman, K.G., Marriott, R.J. and Booth, S.J., Dose reliability of the Serevent Diskhaler system. Pharm. Technol. Int., (1993) 20-27.
8. Sumby, B.S., Cooper, S.M. and Smith, I.J., A comparison of the inspiratory effort required to operate the Diskhaler inhaler and Turbohaler inhaler in the administration of powder drug formulations. Er. J. Clin. Res., 3 (1992) 117-123.
9. Vidgrén, M., Factors influencing lung deposition of inhaled aerosols. Eur. Respir. Rev., 4(18) (1994) 68-70.
10. Vidgren, M., Vidgren, P. and Paronen, P., In vitro deposition of disodium cromoglycate particles inhaled from two dry powder devices. Acta Pharm. Fenn., 97 (1988) 181-186.
11. Wetterlin, K., Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res., 5 (1988) 506-508.
12. Zanen, P., Van Spiegel, P.I., Van der Kolk, H., Tushuizen, E. and Enthoven, R., The effect of the inhalation flow on the performance of a dry powder inhalation system. Int. J. Pharm., 81 (1992) 199-203.